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INTRODUCTION 
NIOSOMES  
           Niosomes or non-ionic surfactant vesicles are microscopic lamellar structures 
formed on admixture of non-ionic surfactant of the alkyl or dialkyl polyglycerol ether 
and cholesterol with subsequent hydration in aqueous media [1]. 
            In Niosomes, the vesicles forming amphiphile is a non-ionic surfactant such as 
span-60 which is usually stabilised by addition of cholesterol and small amount of 
anionic surfactant such as dicetyl phosphate[2]. 
                     
                                            Fig 1: Structure of niosomes 
ADVANTAGES OF NIOSOMES                                                                                                                                          
a) Niosomes offer high patient compliance in comparison with oily dosage from. 
They possess an infrastructure consisting of hydrophilic, amphiphilic and 
lipophilic moieties together and as result can accommodate drug molecules with a 
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wide range as a result can accommodate drug molecules with a wide range of 
solubility. 
b) The characteristics of the vesicle formulation are variable and controllable. 
Altering vesicle composition, size, lamellarity, taped volume, surface charge and 
concentration can control the vesicle characteristics 
c) The vesicles may act as a depot, releasing the drug in a controlled manner 
d) They are osmotically active and stable, as well as they increase the stability of 
entrapped drug. 
e) Handling and storage of surfactants requires no special conditions. 
f) They improve oral bioavailability of poorly absorbed drugs and enhance skin 
penetration of drugs 
g) They can be made to reach the site of action by oral, parenteral as well as topical 
routes. 
PREPARATION METHODS OF NIOSOMES 
A.  Ether injection method[3,4]:  This method provides a means of making Niosomes 
by slowly introducing a solution of surfactant dissolved in diethyl ether into warm 
water maintained at 60oc. The surfactant mixture in ether is injected through 14-guage 
needle into an aqueous solution of material. Vaporization of ether leads to formation 
of single layered vesicles. Depending upon the conditions used the diameter vesicle 
range from 50 to 1000nm. 
B. Hand shaking method (Thin film hydration technique) [4]:   The mixture of 
vesicle forming ingredients like surfactant and cholesterol are dissolved in a volatile 
organic solvent (diethyl ether, chloroform or methanol) in a round bottom flask. The 
organic solvent is removed at room temperature (20oc) using rotator evaporator 
leaving a thin layer of solid mixture deposited on the wall of the flask. The dried 
surfactant film can be rehydrated with aqueous phase at 0-60oc with gentle agitation. 
This process forms typical multilamellar Niosomes.  
Thermosensitive niosomes can be prepared by evaporating the organic 
solvents at 60oc and leaving a thin film of lipid on the wall of rotary flash evaporator 
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[5]. The aqueous phase containing drug is then slowly added with intermittent shaking 
of flask at room temperature followed by sonication. 
C. Sonication [4]: In this method an aliquot of drug solution in buffer is added to the 
surfactant /cholesterol mixture in a 10-ml glass vial. The mixture is probe sonicated at 
60o c for three minutes using a sonicator with a titanium probe to yield niosomes. 
D. Micro fluidization [6]:  Micro fluidisation is a recent technique used to prepare 
unilamellar vesicles of defined size distribution. This method is based on submerged 
jet principle in which to fluidized streams interact at ultra high velocity, in precisely 
defined micro channels within the interaction chamber. The impingement of thin 
liquid sheet long a common front is arranged such that the energy supplied to the 
system remains within the area of Niosomes formation. The result is a greater 
uniformity, smaller size and better reproducibility of Niosomes formed.  
E. Multiple membrane extrusion method [6]:  Mixture of surfactant, cholesterol and 
dicetyl phosphate in chloroform is made into thin film by evaporation. The film is 
hydrated with aqueous drug solution and the resultant suspension extruded through 
polycarbonate membranes, which are placed in series for up to 8 passages. It is a good 
method for controlling niosomes size. 
F. Reverse Phase Evaporation Technique (REV) [5]:  In this method the cholesterol 
and surfactant in 1:1 ratio are dissolved in a mixture of ether and chloroform. An 
aqueous phase containing drug is added to this and the resulting two phases are 
sonicated at 4-5oc. The clear gel is formed is further sonicated after the addition of 
small amount of phosphate buffered saline (PBS). The organic phase is removed at 
40oc under low pressure. The resulting viscous Niosomes suspension is diluted with 
PBS and heated on water bath at 60 c for 10 min to yield Niosomes. 
G.Trans membrane pH gradient(inside acidic)Drug Uptake Process (remote 
Loading) [7]:  Surfactant and cholesterol are dissolved in chloroform. The solvent is 
then evaporated under reduced pressure to get a thin film on the wall of the round 
bottom flask. The film is hydrated with 300 mM citric acid (pH4) by vortex mixing. 
The multi lamellar vesicle are frozen and thawed three times and sonicated. To this 
niosomal suspension aqueous solution containing 10 mg /ml of drug is added and 
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vortexed. The pH of sample is then raised to 7-7.2 with 1M disodium phosphate. The 
mixture is later heated at 60oc for 10 minutes to give niosomes. 
H. The “Bubble” Method [8]:  It is noval technique for the one step preparation of 
liposomes and Niosomes without the use of organic solvents. The bubbling unit 
consists of round bottomed flask with three necks positioned in water bath to control 
the temperature. Water cooled reflex and thermometer is positioned in the first and 
second neck and nitrogen supply through the third neck. Cholesterol and surfactant 
are dispersed together in this buffer (pH 7.4) at 70oc, the dispersion mixed for 15 
seconds with high shear homogenizer Are immediately afterwards “bubbled” at 70oc 
using nitrogen gas. 
I. Formation of Niosomes from proniosomes [9]:  Another method of producing 
Niosomes is to coat a water-soluble carrier such as sorbitol with surfactant. The result 
of the coating process is a dry formulation. In which each water-soluble particle is 
covered with a thin film of dry surfactant. This preparation is termed “proniosomes”. 
The niosomes are recognised by the addition of aqueous phase at T>Tm and brief 
agitation. 
T= Temperature. 
Tm= mean phase transition temperature. 
 
Fig 2:   Figure showing the formation of niosomes from proniosomes 
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Table1: 
Brief example of some drugs incorporated into niosomes using different methods 
 
SEPERATION OF UNENTRAPPED DRUG 
The removal of unentrapped from the vesicles can be accomplished by various 
techniques, which include:  
1. Dialysis [8]: The aqueous nisomal dispersion is dialyzed in a dialysis tubing 
against phosphate buffer or normal saline or glucose solution. 
2. Gel Filtration [9,10]: The unentrapped drug is removed by gel filtration of 
niosomal dispersion through a cephadex-G-50 column and elution with 
phosphate buffered saline or normal saline. 
3. Centrifugation [11,12]: The niosomal suspension is centrifuged and the 
supernatant is separated. The pellet is washed and then resuspended to obtain a 
niosomal suspension from unentrapped drug. 
 
Method of preparation Drug incorporated 
Ether injection  Sodium stibogluconate 
 
 Doxorubicin 
Hand shaking  Methotrexate 
 
 Doxorubicin   
Sonication  9-desglycinamide 
  
 8-arginine 
 
 Vasopressin  Oestradiol  
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CHARECTERISATION OF NIOSOMES 
a. Entrapment efficiency:  After preparing niosomal dispersion, unentrapped drug 
is separated by dialysis, centrifugation, or gel filtration as described above the 
drug remind entrapped in Niosomes is determined by complete vesicle disruption 
using 50% n-propanol or 0.1% triton x-100 and analysing the resultant solution by 
appropriate assay method for the drug. Where, 
                          Entrapment efficiency (EF) = (Amount entrapped total amount) x 100 
b. Vesicular diameter: Niosomes, similar to liposomes, assumes spherical shape 
and so their diameter can be determined using light microscopy, photon-
correlation microscopy and freeze fracture electron microscopy.  
       Freeze thawing [6] (keeping vesicles suspension at-20oc for 24 hours and then 
heating to ambient temperature) of Niosomes increase the vesicle diameter, which 
might be attributed to fusion of vesicles during the cycle. 
c. In vitro release: A method in vitro release rate study includes the use of dialysis 
tubing. A dialysis sac is washed and soaked in distilled water. The vesicle 
suspension is pippeted into a bag made up of tubing and sealed. The bag 
containing the vesicles is placed in 200 ml of buffer solution in a 250 ml beaker 
with constant shaking at 25oc or 37oc. At various time intervals, the buffer is 
analysed for the drug content by an appropriate essay method [9].  
Factors affecting vesicles size, entrapment efficiency and release characteristics: 
a. Drug:  Entrapment of drug in Niosomes increases vesicle size, probably by 
intraction of solute with surfactant head groups, increase in the charge and mutual 
repulsion of the surfactant bilayers, thereby increasing vesicle size [9,12]. In 
polyoxyethylene glycol (peg) coated vesicles, some drug is entrapped in the long 
peg chains, thus reducing the tendency to increase the size [11]. The hydrophilic 
lypophylic balance of the drug effects degree of entrapment. 
b. Amount and type of surfactant: The mean size of niosomes increases 
proportionally with increase in the HLB of surfactants like Span 85 (HLB 1.8) to 
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Span 20 (HLB 8.6) because the surface free energy decreases with an increase in 
hydrophobicity of surfactant [9]. 
The bilayers of the vesicles are either in the so-called liquid state or in gel 
state, depending on the temperature, the type of lipid or surfactant and the presence of 
other components such as cholesterol. In the gel state, alkyl chains are present in a 
well ordered structure, and in the liquid state, the structure of the bilayers is more 
disordered. The surfactants and lipids are characterized by the gel-liquid base 
transition temperature (TC) [9].Phase transition temperature (TC) of surfactant also 
affects entrapment efficiency i.e. Span 60 having higher TC, provides better 
entrapment. 
c. Cholesterol content and charge: inclusion of cholesterol in niosomes increases its 
hydrodynamic diameter and entrapment efficiency [9]. In general, the action of 
cholesterol is two folds; on one hand, cholesterol increases the chain order of 
liquids-state bilayers and on the other, cholesterol decreases the chain orders by gel 
state bilayers. At a high cholesterol concentration, the gel state is transformed to a 
liquid-ordered phase.  
An increase in cholesterol content of the bilayers resulted in a decrease in the 
release rate of encapsulated material and therefore an increase of rigidity of the 
bilayers obtained [12,13,14]. Presence of charge tends to increase the interlamellar 
distance between successive bilayers in multilamellar vesicle structure and leads to 
greater overall entrapped volume. 
d. Methods of preparations: Hand shaking method forms vesicles with greater 
diameter (0.35-13 nm) compared to the ether injection method (50-1000 nm) [6]. 
Small sized niosomes can be produced by reverse phase evaporation (REV) 
method [5,15]. Microfluidization [6] method gives greater uniformity and small size 
vesicles. 
e. Resistance to osmotic stress: Addition of a hypertonic salt solution to a 
suspension of niosomes brings about reduction in diameter. In hypotonic salt 
solution, there is initial slow release slight swelling of vesicle probably due to 
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inhibition eluting fluid from vesicles, followed by faster released, which may be 
due to mechanical loosening of vesicles structure under osmotic stress [1,16].  
 
APPLICATIONS OF NIOSOMES  
Niosomal drug delivery is potentially applicable to many pharmacological 
agents for their actions against various diseases. Some of their therapeutic 
applications are discussed below.  
1) Targeting on bioactive agents 
a. To reticulo-endothelial system (RES): The cells of RES preferentially take up the 
vesicles. The uptake of niosomes by the cells is also by circulating serum factors 
known as opsonins , which mark them for clearance such localized drug 
accumulation has however, been exploited in treatment of animal tumors to 
metastasize to the liver and the spleen and in parasitic infestation of liver [1]. 
b. To organs other than RES: It has been suggested that carrier system can be 
directed to specific site in the body by use of antibodies [17]. Immunoglobulins 
seem to bind quite readily to the lipids surface, thus offering a convenient means 
for targeting drug carrier [18]. Many cells posses the intrinsic abilities to recognise 
and bind particular carbohydrates determinants and these can be exploited to direct 
carrier system to particular cell.  
2. Neoplasia: Doxorubicin, the anthracyclic antibiotic with broad spectrum antitumor 
activity, shows a dose – dependent irreversible cardiotoxic effect. Niosomal 
delivery of this drug to mice bearing S-180 tumor increased their life span and 
decreased the rate of proliferation of sarcoma [19]. Niosomal entrapment increased 
the half-life of the drug, prolonged its circulation and altered its metabolism. Intra 
venous administration of methotrexate entrapped in niosomes to S-180 tumor 
bearing mice resulted in total regression of tumor and also higher plasma level and 
slower elimination [21,20]. 
3. Leishmaniasis: Niosomes can be used for targeting of drug in the treatment of 
diseases in which the infecting organism resides in the organ of reticulo – 
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endothelial system. Leishmaniasis is such a disease in which parasite invades cells 
of liver and spleen. The commonly prescribed drugs are antimonials, which are 
related to arsenic, and at high concentration the damage the heart, liver and kidney. 
4. Delivery of peptide drugs: Yoshida et al [14] investigated oral delivery of 9-
desglycinamide, 8-arginine vasopressin entrapped in niosomes in an in vitro 
intestinal loop model and reported that stability of peptide increased significantly  
5. Immunological applications of niosomes: Niosomes have been used for studying 
the nature of the immune response provoked by antigens. Brewer and Alexander 
[22] have reported niosomes as potent adjuvant in terms of immunological 
selectivity, low toxicity and stability. 
6. Niosomes as carriers for Hemoglobin: Niosomes can be used as carrier for 
hemoglobin. Niosomal suspension shows a visible spectrum of superimposable on 
to that of free hemoglobin. Vesicles are permeable to oxygen and hemoglobin 
dissociation curve can be modified similarly to non-encapsulated 
haemoglobin[23,24]. 
7. Transdermal delivery of drugs by niosomes: Slow penetration of drug through 
skin is the major drawback of transdermal route of delivery an increase in the 
penetration rate has been achieved by transdermal delivery of drug incorporated in 
niosomes Jayraman et al  [25] has studied the topical delivery of erythromycin from 
various formulations including niosomes or hairless mouse. From the studies, and 
confocal microscopy, it was seen that non-ionic vesicles could be formulated to 
target pilosebaceous glands. 
8. Sustained release: Azmin et al [26] suggested the role of liver as a depot for 
methotrexate after niosomes are taken up by a liver cell. Sustained release action of 
niosomes can be applied to drugs with low therapeutic index and low water 
solubility since those could be maintained in the circulation via niosomal 
encapsulation. 
9. Localized drug action: Drug delivery through niosomes is one of the approaches 
to achieve localized drug action, since their size and low penetrability through 
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epithelium and connective tissue keeps the drug localised at the site of 
administration. 
Localized drug action results in enhancements of efficacy of potency of the drug 
and at the same time reduces its systemic toxic effects. (Eg.) Antimonials 
encapsulated within niosomes are taken up by mononuclear cells resulting in 
localization of drug, increase in potency and hence decrease both in dose and 
toxicity[8,27]. 
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DRUG PROFILE 
 
Name              : Levetiracetam 
Brand Name  : Keppra 
Levetiracetam is an anticonvulsant medication used to treat epilepsy. 
Structure Levetiracetam : 
                                        
 
IUPAC Name         : (2R)-2-(2-oxopyrrolidin-1-yl)butanamide 
Chemical Formula : C8H14N2O2 
Molecular weight   : 170.209g/mol 
Half life                  : 6-8 hr 
Solubilty                 : Very soluble in water, Freely soluble in Chloroform, Freely soluble in 
Methanol, Soluble in Ethanol, Sparingly soluble in acetonitrile. 
Categoties             : Anticonvulsants 
                               Nootropic Agents 
Available Form  : 250 mg Tablets, 500 mg tablets. 
  
 
Drug Profile 
 
Dept of Pharmaceutics, KMCH College of Pharmacy       Page 12 
 
 
PHARMACOLOGY 
Mechanism of action 
 The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is 
unknown. The antiepileptic activity of levetiracetam was assessed in a number of animal 
models of epileptic seizures. Levetiracetam did not inhibit single seizures induced by 
maximal stimulation with electrical current or different chemoconvulsants and showed 
only minimal activity in submaximal stimulation and in threshold tests. Protection was 
observed, however, against secondarily generalized activity from focal seizures induced 
by pilocarpine and kainic acid, two chemoconvulsants that induce seizures that mimic 
some features of human complex partial seizures with secondary generalization. 
Levetiracetam also displayed inhibitory properties in the kindling model in rats, another 
model of human complex partial seizures, both during kindling development and in the 
fully kindled state. The predictive value of these animal models for specific types of 
human epilepsy is uncertain. Levetiracetam is thought to stimulate synaptic vesicle protein 
2A (SV2A), inhibiting neurotransmitter release. 
PHARMACOKINETICS 
Absorption 
Rapidly and almost completely absorbed after oral administration (99%). Peak plasma 
concentrations occurring in about an hour following oral administration in fasted subjects. 
Metabolism 
The major metabolic pathway of levetiracetam (24% of dose) is an enzymatic 
hydrolysis of the acetamide group. No CYP450 metabolism detected. 
 
Excretion 
Sixty-six percent (66%) of the dose is renally excreted unchanged. The metabolites 
have no known pharmacological activity and are renally excreted. The mechanism of 
excretion is glomerular filtration with subsequent partial tubular. 
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Toxicity 
Side effects include aggression, agitation, coma, drowsiness, reduced consciousness, 
slowed breathing. 
 
 
Table No2:  Pharmacokinetic profile of Levetiracetam 
Pharmacokinetic Characters Levetiracetam 
bioavailability (%) 
˷ 100% 
protein binding (%) 
<10% 
Volume of distribution(L/Kg) 
             Not Available 
% metabolized 
                 24% 
Elimination T
1/2
(hr) 
    6-8hrs 
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EXCIPIENT PROFILE 
CHOLESTEROL 
 
Name: Cholesterol 
Description: 
The principal sterol of all higher animals, distributed in body tissues, especially the 
brain and spinal cord, and in animal fats and oils. 
Structure of Cholesterol: 
                  
Chemical Formula : C27H46 
Molecular weight   : 386.6535 g/mol 
Melting point          : 148.5oc 
Boiling point           : 360oc 
Water solubility      : 0.095 mg/L ( at 30oc) 
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SPAN 40 
 
Synonym                 : Sorbitan monopalmitate (Span 40) 
Chemical Formula  : C22H42O6 
Molecular weight    : 402.57 g/mol 
Structure of Span 40:  
                             
                                
             
Table 3:  
Properties of Span 40                                
 
                  Related Categoties  
 
Biochemical and Reagents, Cleaners, 
Detergents. 
                   
                  Description 
 
Non-ionic 
 
                  Melting point 
 
46-47oc(lit) 
 
                  HLB value 
 
6.7±10 
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SPAN 60 
Synonym                 :  Sorbitane monostearate, sorbitan stearate 
Chemical Name       :  Span 60 
Chemical Formula  :  C24H46O6 
Description             :  Span 60 is a Sorbitane monostearate then is used as a non-ionic 
                                  detergent. 
Structure of Span 60: 
                             
 
Table 4: 
Properties of Span 60 
 
                  Related Categories  
 
Biochemical and Reagents, Cleaners, 
Detergents, Detergents N toZ,Nonionic. 
                   
                  Description 
 
Non-ionic 
 
                  HLB value 
 
4.7 
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Application: 
Span 60 has been used in a study to assess encapsulation of doxorubicin in niosomes 
as a route to tumor targeting. It has also been used in a study to investigate the use of non-
ionic surfactants as contrast agents for use in diagnostic ultrasounds. 
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LITERATURE REVIEW  
 
 Raja K. et al29 Formulated and evaluated the Maltodextrin based Proniosomal Drug 
Delivery System containing Anti-diabetic (Glipizide) drug to avoid many of the problems 
associated with aqueous niosome dispersions and problems of physical stability 
(aggregation, fusion, leaking) could be minimized.  Maltodextrin-based proniosomes are 
a potentially scalable method for producing niosomes for delivery of hydrophobic or 
amphiphilic drugs.  The optimized formulation developed using the desirability approach 
produced high drug encapsulation efficiency and sustained anti-diabetic activity in rats 
following oral administration. 
 
 Rajesh Z. Mujoriya, Kishordhamonder et al30 Niosomes  drug delivery system. 
Niosomes are thoughts to be better candidate’s drug delivery as compared to liposomes 
due to various factors like cost, stability etc. Various type of drug deliveries can be 
possible using niosomes like targeting, ophthalmic, topical, parentral, etc. Niosomes are 
thoughts to be better candidate’s drug delivery as compared to liposomes due to various 
factors like cost, stability etc. Various type of drug deliveries can be possible using 
niosomes like targeting, ophthalmic, topical, parentral, etc.  
 
 Anchal Sankhyan and Pravin Pawar31 Recent Trends in Niosome as Vesicular Drug 
Delivery System. The article focuses on various advantages of vesicular systems 
(niosomes) to develop the effective delivery system to achieve maximum effective 
concentration. Niosomes, nonionic surfactant vesicles with lamellar structure which may 
be unilamellar and multilamellar serve to be efficient in providing these required 
advantages. Niosomes are novel drug delivery system which offers a large number of 
advantages over other conventional and vesicular delivery systems. From the above 
compilation of work it can be concluded that niosomes have suitability for encapsulating 
a varied variety of drugs and also the benefits offered by niosomes are also widely 
exploited. Niosomes have evolved for treatment of many dreadful diseases efficiently 
with reduced side effects and better patient compliance. Thus niosomes present itself as a 
versatile tool in therapeutics.  
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 P. Prabhu et al 32 Prepared and evaluated the niosomes of brimonidine tartrate as ocular 
drug delivery system by film hydration method and evaluated for photomicroscopic 
characteristics, entrapment efficiency, in vitro, ex- in vitro drug release, in vivo intra 
ocular pressure lowering activity.  The in vitro and ex- in vitro drug release studies 
showed that, there was slow and prolonged release of drug from all the formulations and 
followed zero order kinetics. 
 
 Sabarikumar K. et al33 Performed bioavailability enhancement of aceclofenac niosomes 
containing surfactants and cholesterol.  The aim of the study was to develop and evaluate 
niosomal formulation of Aceclofenac in order to improve its bioavailability.  The results 
of in vitro drug release studies showed that formulation (ANF-3) has better modified and 
extended over release of drug (92.19%) for 72hrs. ANF-3 emerged as the most 
satisfactory formulation in so far as its properties were concerned. 
 
 N. Pavala Rani et al 34 Formulated and evaluated rifampicin and gatifloxacin niosomes 
on logarithmic-phase cultures of Mycobacterium tuberculosis.  The bactericidal activities 
of the niosomal formulation were studied by BACTEC radiometric method using the 
resistant strains (RF 8554) and sensitive strains (H37Rv) of Mycobacterium tuberculosis 
which showed greater inhibition and reduced growth index.  Niosomes of rifampicin and 
gatifloxacin were prepared by lipid hydration technique using rotary flash evaporator.  
The in vitro release study showed that 98.98% and 97.74% of release of rifampicin and 
gatifloxacin niosomes respectively. 
 
 Darwish, I.A. et al 35 Evaluated crown ether based niosomes as cation containing and 
cation sensitive drug delivery systems.  The release of the fluorescent marker rhodamine 
B from PCE/CHOL niosomes was slightly increased by the addition of calcium ions but 
remained unaffected by the addition of sodium ions.  This is thought to be due to a 
slightly greater ease of divalent cation chelation by the crown ether head groups when 
compared to the monovalent cation, the latter of which are more highly solvated in 
aqueous solution.  This is the first study on the effect of ions on the release properties of 
crown ether based niosomes.  These systems may be developed as cation containing or 
cation sensitive release systems for drug delivery and other industrial uses. 
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 Ahmed N. Allam et al 36Formulated and evaluated the Acyclovir niosomes for 
ophthalmic use.  Niosomes are prepared using two different methods namely: film 
hydration method (FHM) and reverse phase evaporation method (REV).  The study 
includes qualitative ocular irritation testing.  The data obtained from corneal permeation 
studies showed that the cumulative amount permeated from most niosomal formulations 
was lower than that from drug solution, except with those corresponding to cholesterol: 
surfactant molar ratio 1:1. 
 
 Vijay D. Wagh et al 37 Formulated and evaluated itraconazole niosomes drug delivery 
system and its antimycotic activity against Candida albicans.  Formulated niosomes were 
evaluated for vesicle size, entrapment efficiency, drug release, skin permeation, and 
antimycotic activity.  Itraconazole niosomes were having larger zone of inhibition than 
marketed formulation when activity was checked against C. albicans. 
 
 Vyasjigar* et al 38 Formulated and evaluated of topical niosomal gel of erythromycin in 
various parameter. Erythromycin is macrolide antibiotic used commonly for the treatment 
of acne either single (or) in combination. The finding of this investigation have 
conclusively demonstrated that encapsulation of  Erythromycin in to niosomal gel 
formulatin improves skin retention which may be reflected, based on prior hypothesis, as 
improved therapeutic response and reduce  adverse symptoms. 
 
 V. Lokeswara Babu et al 39 Formulated and evaluated by using different Novel Drug 
Delivery System (NDDS) which are used for targeting drugs to different organ system 
and for controlled/sustained release of drug from the dosage form Niosomal Drug 
Delivery System is suitable for encapsulating toxic anti cancer drugs, anti-infective 
drugs,anti AIDS drugs etc. 
 
 Loscher W et al 40 Antiepileptogenic effect of the novel anticonvulsant levetiracetam in 
the kindling model of temporal lobe epilepsy. We have previously shown that novel 
anticonvulsant levetiracetam exerts potent anticonvulsant activity against both focal and 
generalized seizures in fully amygdale-kindled rats, i.e., a model of temporal lobe 
epilepsy. We determined the pharmokokinetics of the drug after i.p. injection. 
Levetiracetam hada relative short half-life 2-3 hr.when rats were treated with 
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levetiracetam during kindling acquisition at daily i.p. doses of 13,27 or 54 mg/kg, the 
drug dose dependently suppressed the increase in seizure severity and duration induced 
by repeated amygdale stimulation. Adverse effect were not observed at any dose of 
levetiracetam tested in kindled rats.  
 
 Amish Ashvinkumar Dangi et al 41 Formulation and Evaluation of Colon Targeted Drug 
Delivery System of Levetiracetam using Pectin as Polymeric Carrier: The aim of the 
present work was to develop and evaluate colon specific sustained release tablet using 
levetiracetam (LEV), microbially degradable polymeric carrier (pectin), coating material 
and matrix forming polymers. Pectin, drug and physical mixture were evaluated for 
incompatibility study by Fourier transform infrared spectroscopy (FTIR) and differential 
scanning calorimetry (DSC). All the batches of matrix tablet (F1-F4) were subjected for 
in-vitro dissolution in various simulated gastric fluids for suitability for colon specific 
drug delivery system. The studies confirmed that, the designed formulation could be used 
potentially for colon delivery by controlling drug release in stomach and the small 
intestine. The prepared tablets met the compendia limits in terms of physiochemical 
parameters and dissolution studies. As a result, colon delivery of levetiracetam appeared 
to be a promising alternative to traditional drug administration routes.  
 
 Balaiah et al 42 Formulation Development and In-Vitro Characterization of Oral 
Levetiracetam: Levetiracetam is a second-generation antiepileptic agent useful in the 
treatment of partial onset and myoclonic seizures, which has short plasma half-life of 7 ± 
1 hour in adults along with bitter taste and faint odor. Preformulation studies were carried 
out to rule out any drug-polymer interactions by DSC technique. In the in vitro release 
studies initial burst release was observed from all the formulations. The most satisfactory 
formulation released drug for 24hours. SEM studies of the most satisfactory formulation 
showed that the microspheres were spherical and porous in nature. The data obtained 
from in vitro release showed highest correlation with Higuchi model and the drug release 
was found to be diffusion controlled.the physico-chemical parameters and in vitro drug 
release profile requirements for an oral controlled release microsphere formulation of 
leviteracetam, in addition to masking the bitter taste and faint odor of the drug. 
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 Hasan H. Sonmezturk et al 43  Levetiracetam Extended Release as Adjuvant Therapy for 
the Control of Partial-onset Seizures. The precise mechanism of action is unknown. 
Animal studies showed binding to synaptic vesicle protein SV2A, thought to be involved 
in modulating synaptic neurotransmitter release. LEV-IR is proven effective as adjunctive 
therapy for partial-onset seizures, It was shown to be equivalent to carbam azepine as 
first-line treatment for partial-onset seizures. The extended release formulation added 
advantages such as better tolerance and increased compliance. LEV-XR is demonstrated 
to be safe and effective add-on treatment for partial onset seizures in adult patients.  
 
 Sakthivel et al44 Formulation and Invitro Evalution of Niosomes contaninng 
Oxacarbazepine. Niosomes are the novel vesicular drug delivery system by which we can 
achieve the constant plasma drug concentration for the extended period of time. 
Oxcarbazepine niosomes were prepared by thin film hydration method using span60 in 
order to achieve prolonged circulation time and sustained release. From this study it was 
observed that the formulation F-II showed satisfactory particle size 230-275nm, 
entrapment efficiency 58.87% and in vitro release 78.08% for the period of 16 hours. 
Thus the niosomal formulation could be a promising delivery system for Oxcarbazepine 
with improved anticonvulsant activity, stability and sustained drug release profile. 
Niosomes containing Oxcarbazepine were formulated using different surfactants such as 
span 40, span 60 and span 80 and evaluated for various parameters. Thus the prepared 
noisome could be promising delivery system for Oxcarbazepine with sustained drug 
release profiles.  
 
 Tim De Smedt et al45 Levetiracetam: Part II, the Clinical Profile of a Novel 
Anticonvulsant Drug. The objective of this article was to review and summarize the 
available reports on the profile of the novel anticonvulsant drug levetiracetam (LEV) in a 
clinical setting. This article is devoted to the clinical pharmacology and clinical trials of 
LEV investigating its efficacy and safety as add-on therapy or monotherapy for various 
seizure types. LEV is shown to be a safe, broad-spectrum anticonvulsant drug with highly 
beneficial pharmacokinetic properties, a favorable long-term retention rate, and a high 
responder rate, indicating that LEV is an efficient therapeutic option for the treatment of 
several types of epilepsy. In a clinical setting, LEV has proven to be a well tolerated and 
 Literature Review 
 
Dept of Pharmaceutics, KMCH College of Pharmacy       Page 23 
 
efficacious ACD against a broad range of seizure types. a broad range of seizure types. In 
conclusion, LEV is a safe and unique addition to ACDs used in clinical practice.   
 
 S. Poongothai et al46 A Sensitive Dissolution Test Method for the Development and 
Validation of Levetiracetam Tablets by Reverse Phase-HPLC Technique. This study 
describes the development and validation of dissolution tests for levetiracetam tablets 
using a reverse phase high performance liquid chromatography method. Optimal 
conditions to carry out the dissolution tests were 900 mL of purified water as dissolution 
medium, paddle at 50 rotations per minute (rpm) stirring speed for tablets and detection 
was carried out at 217 nm. The obtained results provided adequate dissolution profiles. 
The HPLC method was validated to meet requirements for a global regulatory filing and 
also to quantify levetiracetam tablets from the dissolution tests.  
 
 V. Pola Chandu et al47 Niosomes: A Novel Drug Delivery System. Niosome are non-
ionic surfactant vesicles obtained on hydration of synthetic nonionic surfactants, with or 
without incorporation of cholesterol or their lipids. They are vesicular systems similar to 
liposomes that can be used as carriers of amphiphilic and lipophilic drugs. Niosomes can 
entrap both hydrophilic and lipophilic drugs and can prolong the circulation of the 
entrapped drug in body. This review article focuses on the advantages, Disadvantages, 
preparation methods, factors affecting, characterizations, invitro methods, drug release 
kinetics, and applications of noisome.   
 
 Kandikonda Saikrishna et al.48 New Rp-Hplc Method For The Determination of 
Levetiracetam In Bulk And Prepared Tablets. A simple Reverse Phase HPLC method was 
developed for the determination of LEVETIRACETAM (LCM) present in bulk and 
prepared tablets. An ODS C18 (250cm ´4.6 mm) column from Shimadzu in gradient 
mode, with mobile phase acetonitrile: KH2PO4 buffer [0.05M] (50:50) was used. The 
proposed method is precise, accurate, reproducible and rapid for the determination of 
Levetiracetam in bulk and their pharmaceutical dosage forms.  
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AIM AND OBJECTIVE 
 
AIM: 
 To formulate and evaluate Levetiracetam niosomes and compare its anti-convulsant 
activity with the pure drug. 
  OBJECTIVE: 
 To prepare  and evaluate Levetiracetam niosomes .  
 The need for present study is to encapsulate the drug in the niosomes vesicles for 
effective central nervous system drug delivery for the prolonged period of time. 
 To compare the anti convulsant activity of Levetiracetam niosomes with a 
Levetiracetam pure drug. 
 To formulate Levetiracetam in niosomal drug delivery there by dose can be 
minimised and also to achieve sustained release for a prolonged period of time. 
 To carry out the stability studies on the optimised formulation of niosomes as per ICH 
guidelines. 
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PLAN OF WORK 
 
 Pre-formulation studies 
 Solubility: To study the solubility behaviour of the drug with different 
solvent. 
 FTIR: Identification of levetiracetam in pure drug by FTIR technique. 
 DSC: To observe the compatibility of the product and excipients used 
in the formulations. 
 Optimization of the formula: 
 Optimization of excipients (surfactants). 
 Optimization of rotating speed. 
 Optimization of temperature. 
 To formulate the levetiracetam niosomes with different surfactants by liquid 
hydration      technique using Rotator Flash Evaporator. 
 To characterize the formulated niosomes by following methods. 
 Surface Morphology. 
 Particle size distribution of the prepared niosomes. 
 Determination of entrapment efficiency. 
 To test the stability of the formulated niosomes. 
 To test the sterility of the formulated niosomes. 
 To examine In-vitro diffusion study of the niosomes prepared with different in 
the surfactants and to compare the drug release profile. 
 To test the anti-convulsant activity of the formulated niosome with the 
formulation having best drug release. 
 The animals are to be weighed numbered. They should be divided in to 4 groups 
each consisting of 4-6 mice. one group will be used as control and the other 
group for treatment. 
 The animal should be hold properly, the corneal electrode will be placed on the 
cornea and prescribed current will be applied. 
 The different stages of convulsion are to be noted (i.e). 
 Tonic flexation 
 Tonic extension 
 Clonic convulsion 
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 Stupor 
 Recovery (or) death. 
 
 The time spent by the animal in each phase of convulsion is to be noted. 
 The experiment will be repeated with other animal of control group. 
 Drug sample will be injected intraperitonially to a group of mice and after 30 
min, the animal will be subjected to electro convulsion as described in step-2. 
 The reduction in abolism of tonic extension of MES convulsion will be noted. 
 
  
Materials and Methodology 
 
Dept of Pharmaceutics, KMCH College of Pharmacy       Page 27 
 
MATERIALS AND METHODOLOGY 
Table No 5: List of Materials used 
S.NO. MATERIALS 
USED 
MANUFACTURER 
1. Levetiracetam Lupin 
2. Cholesterol Qualigens Fine Chemicals, 
Mumbai 
3. Span 40 Kemphasol 
4. Span 60 Kemphasol 
5. Chloroform Ranbaxy 
6. Diethylether Qualigens Fine Chemicals, 
Mumbai 
7. Buffer (pH 7.4) Laboratory preparation 
8. Mice Seiss Albino mice (25-30) 
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Table No 6: List of Equipments used 
S.NO. EQUIPMENTS MANUFACTURER 
1 Rotary Flash Evaporator Equitron Roteva,Medica 
Instrument Mfg-Co, Mumbai 
2 Ultra Sonicator Vibronics 
3 UV-Double Beam 
Spectrophotometer 
UV-Pharmaspec 1700, 
Shimadzu 
4 Electronic Balance Sartorius 
5 pH Meter Elico LI 120 
6 Magnetic stirrer Remi- 1MLH 
7 Environment stability 
testing chamber 
“HECO”. Environment 
chamber 
8 FTIR Perkin Elmer 
9 Centrifuge Remi 
10 Scanning Electronic 
Microscope 
JEOL, JSM -6701 F, Japan 
 11 Particle size Analyzer Microtrac – Bluewave US 
       12 Anti convulsometer Kmch Laboratory 
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METHODOLOGY 
PREFORMULATION STUDY 
                     Preformulation study is one of the important prerequisites in development 
of any drug delivery system. Thus, a preformulation study was carried out to check the 
compatibility between drug and various excipients and development of analytical method 
of drug. 
DRUG EXCIPIENT COMPATIBILITY STUDIES 
           FT-IR spectra matching approach was used for detection of any possible 
chemical interaction between drug and excipients. A physical mixture (1:1:1) of 
drug,cholesterol and surfactants (span40,span60) was prepared and mixed with the 
suitable quantity of potassium bromide. About 100mg of mixture was compressed to 
form a transparent pellet using a hydraulic press at 6 tons pressure. It was scanned from 
4000 to 400 cm-1 in FT-IR spectrometer. The IR spectrum of the physical mixture was 
compared with those of pure drug and excipients and matching was done to detect any 
appearance or disappearance of peaks. This study was done by using SHIMADZU FT/IR 
spectrum. 
  
DIFFERENTIAL SCANNING CALORIMETER 
The DSC curves of levetiracetam, Cholesterol, and surfactant (span 40,span 60) Physical 
mixture of Levetiracetam were obtained using  differential scanning calorimeter (DSC 
Q20 V24.2 Build 107) increasing heating rate at 10˚ C/min and heated over a 
temperature range of 50˚ C to 250˚ C in an atmosphere of nitrogen (20ml/min). 
Accurately twelve mg of sample was taken in a hermetically sealed, flat bottom 
aluminum sealed pan and placed at sample stage and thermograms were recorded. 
 
PREPARATION OF STANDARD CURVE FOR LEVETIRACETAM NIOSOMES 
Preparation of phosphate buffer pH 7.4  
Dissolve 125 ml of 0.2M potassium dihydrogen phosphate and 195.5 ml 0.2M 
sodium hydroxide in 500 ml of distilled water. 
 
 
 
  
Materials and Methodology 
 
Dept of Pharmaceutics, KMCH College of Pharmacy       Page 30 
 
Determination of λmax of Levetiracetam 
 
 50 mg of accurately weighed drug was dissolved in the phosphate buffer pH 7.4 
which upon suitable dilution, analyzed in UV spectrophotometer between 200 to 400 nm. 
The point of absorption maximum obtained in the graph was considered as the max of 
the pure drug. 
Preparation of standard curve 
 100mg of Levetiracetam pure drug was dissolved in 100 ml of phosphate buffer 
pH 7.4 (solution A). 
 From the solution A, 2.5 ml was pipetted out and made up to 25 ml with 
phosphate buffer pH 7.4 (solution B). 
 From the solution B, serial dilutions were made to produce 0.5, 1, 1.5, 2, 2.5, 3, 
and 5µg/ml concentrations. 
 These samples were analysed spectrophotometrically at 220 nm usin phosphate 
buffer pH 7.4 as blank. 
  
FORMULATION DEVELOPMENT OF NIOSOMES CONTAINING 
LEVETIRACETAM 
Levetiracetam niosomes were prepared by Thin film hydration technique by 
handshaking method. 
 According to this method, accurately weighed quantity of cholesterol and non-
ionic surfactant were dissolved in 5ml of chloroform and poured into a round bottom 
flask.  The flask was rotated at 1.5 cm above a water bath at 60oC 20c under reduced 
pressure, until all the organic phase evaporated and a thin layer was formed on the wall 
of a round bottom flask.  Then accurately weighed quantity of drug was dissolved in 5ml 
of phosphate buffer.  The dried non- ionic surfactant and cholesterol film was 
subsequently hydrated with this drug solution and the mixture was rotated by immersing 
in a water bath at 60oC 20c for 1 hour until a good dispersion of mixture was obtained.  
The niosomes vesicles containing were subsequently formed.  The suspension was then 
sonicated to form unilamellar vesicles. 
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Preparation of Niosomes 
Hand shaking method (Thin film hydration technique)4:   The mixture of vesicle 
forming ingredients like surfactant and cholesterol are dissolved in a volatile organic 
solvent (diethyl ether, chloroform or methanol) in a round bottom flask. The organic 
solvent is removed at room temperature (20oc) using rotator evaporator leaving a thin 
layer of solid mixture deposited on the wall of the flask. The dried surfactant film can be 
rehydrated with aqueous phase at 0-60oc with gentle agitation. This process forms typical 
multilamellar Niosomes.  
Thermosensitive niosomes can be prepared by evaporating the organic solvents at 
60oc and leaving a thin film of lipid on the wall of rotary flash evaporator. The aqueous 
phase containing drug is then slowly added with intermittent shaking of flask at room 
temperature followed by sonication. 
 
 Table No 7: Formulation Chart of Niosomes Containing Levetiracetam 
 
 
 
 
 
 
 
 
 
  
Formulation code             FI                   FII 
Amount of Levetiracetam            5mg         5mg 
Cholesterol            5mg         5mg 
Span40            5mg           - 
Span 60               -         5mg 
Chloroform            5ml         5ml 
Phosphate Buffer            5ml         5ml 
Cholesterol surfactant ratio            1:1         1:1 
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Table 8: Formulation code 
S. No Formulation code Type Of Surfactant Used 
1. FI Span 40 
2. FII Span 60 
 
EVALUATION OF LEVETIRACETAM NIOSOMES 
 
Optical microscopy29 
Optical microscopy shows niosomes under magnification of 40X. 
 
Transmission Electron microscopic observation72 
The niosomal dispersion was spread on the glass slide using a glass rod. 
Formation of multilamellar vesicles was confirmed by examining the niosomal 
suspension under an transmission electron microscope with the magnification power of 
71 lacks Sx. 
 
Vesicle shape42 
The vesicle shape of best formulation F2 was determined by using scanning 
electron microscopy. 
Entrapment efficiency41 
An1ml of the sample is taken and centrifuged at 13000 RPM at 40c for 60 
minutes using Eppendorf centrifuge.  Supernatant was separated without disturbing the 
sediment layer using micropipette.  Then the supernatant layer (free drug) was diluted 
using PBS pH 7.4 and analysed using UV spectrophotometer at 220 nm. 
Percent drug entrapment  = amount of drug entrapped/initial amount of drug*100 
 
In vitro diffusion study of Levetiracetam niosomes71: 
The in vitro release of niosomes was studied by using simple diffusion cell 
apparatus.  The diffusion cell apparatus consists of a glass tube with an inner diameter of 
2.5 cm, open at both ends, one end of the tube is tied with cellophane membrane. The 
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cellophane membrane soaked in glycerin for 6-8 hours. It was clamped carefully between 
donor and receptor compartment. Niosomes equivalent to 5mg of Levetiracetam was 
taken in a dialysis tube and placed in 200ml of Phosphate buffer 7.4.  The medium was 
stirred by using the magnetic stirrer and the temperature was maintained at 3720C.  
Periodically, 5 ml of samples were withdrawn and after each withdrawal same volume of 
medium was replaced.  Then the samples were assayed spectrophotometrically at 220 nm 
using phosphate buffer as blank. 
RELEASE KINETICS 70 
 The results of in vitro release profile obtained for all the formulations were 
plotted in modes of data treatment as follows. 
1. Log cumulative percent drug remaining versus time (first order kinetic model)  
2. Cumulative percent drug release versus time (zero order kinetic model) 
3. Cumulative percent drug release versus square root of time (Higuchi’s model) 
Drug release kinetics- model fitting of the diffusion data 
  It is necessary to ensure that drug diffusion occurs in an appropriate manner. 
Drug diffusion from solid dosage forms has been described by kinetic models in which 
the dissolved amount of drug (Q) is a function of the test time, t or Q = f (t). Some 
analytical definitions of the Q (t) function are commonly used such as zero order, first 
order, Higuchi,  models. Other release parameters, such as diffusion time (tx%), diffusion 
efficacy (ED), difference factor (f1), similarity factor (f2 ) can be used to characterize 
drug diffusion / release profile.  
 Zero order kinetics 
 A zero-order release would be predicted by the following equation.  
                 At    =   Ao - Kot            eq…….. (1) 
Where, 
 At    =    Drug release at time” t” 
 Ao   =     Initial drug concentration 
 Ko   =     Zero-order rate constant (hr) 
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  When the data is plotted as cumulative percent drug release versus time if the 
plot is linear then the data obeys zero-order release kinetics, with a slope equal to ko. 
 
Use:  The pharmaceutical dosage forms following this profile release the same amount of 
drug by unit of time and it is the ideal method of drug release in order to achieve a 
prolonged pharmacological action. 
 
First order kinetics 
 A first order release would be predicted by the following equation. 
                  Log C    =      Log Co - Kt / 2.303          eq……. (2) 
Where 
 C   =   Amount of drug remained at time” t” 
 Co =   Initial amount of drug 
 Kt    =    First-order rate constant 
 When the data is plotted as log cumulative percent drug remaining versus time 
yields a straight line indicating the release follows first-order kinetics, the constant k can 
be obtained by multiplying 2.303 with slope values 
Use:  The pharmaceutical dosage forms containing water-soluble drugs in porous 
matrices, follows this type of diffusion profile. The release of the drug is proportional to 
the amount of drug remaining in its interior so that the amount of drug release by unit of 
time diminishes. 
 Higuchi model 
 Drug release from the matrix devices by diffusion has been described by 
following higuchi’s classical diffusion equation. 
    Q = [DE/ τ(2A- ECs) Cst ]                 eq  ( 3) 
Where, 
Q   =   Amount of drug release at time” t” 
D   =   Diffusion coefficient of the drug in the matrix 
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A    =   Total amount of drug in unit volume of matrix 
Cs   =   The solubility of the drug in the matrix 
E     =   Porosity of the matrix 
T     =   Time in hrs at which q is the amount of drug is release 
                Equation 3 may be simplified if one assumes that D, Cs and A are constant.  
Then equation-3 becomes 
   Q    =    K t ½      eq  (4) 
 When the data is plotted according to equation-4 i.e. cumulative drug release 
versus Square root of time yields a straight line, indicating that the drug was released by 
diffusion mechanism. The slope is equal to k. 
 
Use:  The relation can be used to describe the drug diffusion from several types of 
modified release pharmaceutical dosage forms, as in case of some water soluble drugs. 
 
STABILITY STUDIES41-42 
Pharmaceutical preparations or products often may exhibit physical or chemical 
reactions and that may end in instability. Due to such instability, the preparation gets 
deteriorated. This deterioration may lead to 
(a) Reduction in the activity of a preparation. 
(b) Formation of toxic products. 
(c) An inelegant product. 
Apart from these effects, microbial contamination also may cause deterioration of 
the product. Ultimately, the product becomes unacceptable.  Hence it is necessary to 
perform stability testing to find out the extent of deterioration or degradation and to 
ensure the degradation has not exceeded an acceptable level assuring, 
1) The safety of the patient and 
2) The activity of the product. 
So, the formulated niosomes were subjected for stability studies for a period of 
three months.  The formulated niosomes were divided into 3 portions.  First portion was 
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kept at refrigeration (40C10C) temperature.  Second portion was kept at room 
temperature.  Third portion was kept at 400C20C, 70% 5 %. Optimized niosomal 
formulation was selected for stability studies of vesicles. 
STERILITY TEST69  
 0.2ml of given sample of 10% concentration of medium is used and inoculated 
into three tubes, i.e 3 blanks, 3 possitive controls and 3 negative controls. 
 Nutrient media used to check the presence of aerobic and anerobic organisms. 
 Sabourands agar medium is used to check fungi kept at 37oC. 
 Incubate and observe the growth after 24 hours. 
 All the media are adjusted to PH (7.2-7.6) and sterilized by autoclaving at 121oC 
for 20 minutes. Sterility of these media should also be tested. 
 All above tests are conducted and observed for 7 days. 
ANTICONVULSANT ACTIVITY68 
 The animals are to be weighed numbered. They should be divided in to 4 groups 
each consisting of 4-6 mice. one group will be used as control and the other group 
for treatment. 
 The animal should be hold properly, the corneal electrode will be placed on the 
cornea and prescribed current will be applied. 
 The different stages of convulsion are to be noted (i.e). 
i. Tonic flexation 
ii. Tonic extension 
iii. Clonic convulsion 
iv. Stupor 
v. Recovery (or) death. 
 The time spent by the animal in each phase of convulsion is to be noted. 
 The experiment will be repeated with other animal of control group. 
 Drug sample will be injected intraperitonially to a group of mice and after 30 min, 
the animal will be subjected to electroconvulsion as described in step-2. 
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 The reduction in abolism of tonic extension of MES convulsion will be noted. 
Aimals   :  Seiss Albino mice (25-30) 
Gender  :  Male/Female 
Number to be used :  24 
Duration  :  1 month 
 
Table 9: Grouping of Animals 
 
Group Treatment : Dose and Route of 
Administration 
No of Animals 
(mice) 
1 Control (only vehicle) 6 
2 Only MES induced 6 
3 MES with standard (Levetiracetam plain) 6 
4 MES of Levetiracetam niosomes 6 
 
 
 
 
 
 
                                                                                                                               
Results and Discussion 
 
Dept of Pharmaceutics, KMCH College of Pharmacy       Page 38 
 
 
RESULTS & DISCUSSION 
Table 10: Solubility Studies of Levetiracetam 
 
SOLVENTS 
 
SOLUBILITY 
 
               Water Highly soluble in water 
 
                Diethyl ether Highly soluble in water 
 
                Chloroform Freely soluble in water 
 
                Methanol Freely soluble in water 
 
                Ethanol soluble in water 
 
                Acetonitrile Sparingly soluble in 
acetonitrile 
 
DRUG EXCIPIENT COMPATIBILITY STUDIES 
                         Figure 3: FT-IR Spectrum of Levetiracetam pure drug 
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Table No 11: FT-IR Spectrum of Levetiracetam pure drug 
Peak 
 
Group 
3360 Aliphatic primary amine 
3187,2937 CH Stretching 
1675 O=C-NH2  
703.89,636 Out of plane N-H Wagging 
                   
                          Figure 4: FT-IR Spectrum of Cholesterol 
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Figure 5: FT-IR Spectrum of Span 40 
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Table No 12: FT-IR Spectrum of Span 40 
Peak Tr Group 
3366 Aliphatic primary amine 
2917,2849 CH Stretching vibration 
1735 O=C Stretching vibration 
1654 O=C-NH2 Group 
 
 
Figure 6: FT-IR Spectrum of Span 60 
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Figure 7: FT-IR Spectrum of Drug+ Cholesterol+Span40 
 
 
 
 
Table No 13: FT-IR Spectrum of Drug+ Cholesterol+Span40 
Peak 
 
Group 
3360 Aliphatic primary amine 
3187,2937 CH Stretching 
1675 O=C-NH2 
703.89,636 Out of plane N-H Wagging 
 
Figure 8: FT-IR Spectrum of Drug+ Cholesterol+Span60 
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DIFFERENTIAL SCANNING CALORIMETRY STUDIES 
DSC thermogram of Levetiracetam and mixture’s are depicted in                     
(Figure 9, 10, 11, 12, 13, 14), respectively. The thermogram of pure drug, cholesterol, 
span40, span60 exhibited a sharp endothermic peak at 192.53˚ C, 140.76 oC, 53.14 oC, 
57.84 oC. Corresponding to its melting point respectively,while the mixture’s  
exhibited a broad endothermic peak at 51.96˚C, 56.80oC.  The DSC thermogram of 
cholesterol , span40, span60 and levetiracetam mixture showed identical peaks 
corresponding to pure drug indicated the absence of well defined chemical interaction 
between the drug and the excipients. 
 
                           
Figure 9: DSC of Levetiracetam pure drug 
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Figure 10: DSC of Cholesterol 
 
 
                             
 
Figure 11: DSC of Span 40 
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                                 Figure 12: DSC of Span 60 
 
 
Figure 13: DSC of Drug+ Cholesterol+Span40 
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                    Figure 14: DSC of Drug+ Cholesterol+Span60 
 
 
Table 14: DSC Observed for the Drug and excipients  
 
 
CALIBRATION CURVE OF LEVETIRACETAM 
 
A calibration curve for Levetiracetam was constructed in pH 7.4 phosphate 
buffer, wave length at 220nm using UV Spectrophotometer. The linearity of 
calibration curve was found to be in the range of 5-30µg/ml. A regression coefficient 
value of 0.992 was noticed for Levetiracetam. 
 
 
           S.NO                SAMPLE MELTING POINT 
              1 Levetiracetam 192.53oC 
              2 Cholesterol 140.76oC 
              3 Span 40 53.14oC 
              4 Span 60 57.84oC 
              5 Drug+Cholesterol+Span 40 51.96oC 
     6 Drug+Cholesterol+Span 60 56.80oC 
                                                                                                                               
Results and Discussion 
 
Dept of Pharmaceutics, KMCH College of Pharmacy       Page 46 
 
 
Figure 15: Standard calibration curve of Levetiracetam 
 
 
 
Table No 15: Calibration curve of Levetiracetam  
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Table 16: Optimization of temperature during niosomes preparation 
   S.NO. TEMPERATURES OBSERVATION 
   1. Below 600 C Irregular Shaped vesicles were formed. 
   2. 600 C 20 C Spherical vesicles were formed. 
   3. Above 800 C Less and irregular vesicles were formed. 
 
 
Table 17: Optimization of Rotating speed 
    S.NO    RPM OBSERVATION 
    1. Below 80 Clumped vesicles were formed. 
    2. 100  2 Spherical vesicles were formed. 
    3. Above 100 Irregular shaped vesicles were formed. 
 
 
Table 18: Optimization of temperature during Ultrasonication 
    S.NO.    TEMPERATURES OBSERVATION 
1. Below 100 C Small sized vesicles were formed. 
2. 10-200 C Numerous vesicles of moderate size. 
3. Room temperature Large sized vesicles. 
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Table 19: Optimization of Ultrasonication time 
   S.NO. TIME OBSERVATION 
1. 10 Mins Incomplete and large sized vesicles were formed. 
2. 15 Mins Spherical vesicles were formed. 
3. 30 Mins Broken vesicles were formed. 
 
Table 20: Selection of Surfactant 
   S.NO.   SURFACTANT OBSERVATION 
   1.    Span 40 Less vesicles were formed. 
   2.    Span 60 Good number of vesicles were formed. 
 
Formulation development of Niosomes containing Levetitracetam 
Various formulations of Niosomes were developed for Levetiracetam by Hand 
shaking method. The formulation of Levetiracetam niosomes was also prepared by 
thin film  hydration technique. Before the formulation of Niosomes were subjected to 
internal morphology, vesicle shape are given in Figure:-17-18 and entrapment 
efficiency values are given in Table No: 22.  
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EVALUATION OF PHYSICO CHEMICAL PARAMETERS 
Optical microscopy 
Optical microscopy observed niosomes under magnification of 40X of F1 and 
F2.The scale is 50 µm. 
              FORMULATION 1                                           FORMULATION 2 
       
                     Fig 16: Optical microscopy A) Formulation 1 B) Formulation 2 
Transmission Electron microscopic observation 
Formation of multilamellar vesicles was confirmed by examining the niosomal 
suspension under an transmission electron microscope with the magnification power 
of 71 lacks Sx and observe the internal morphology. 
      FORMULATION 1    FORMULATION 2 
    
              Fig 17: Transmission Electron microscopic observation 
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Vesicle shape by SEM Technique 
The formulated niosomal vesicles were confirmed by scanning electron microscopy in 
the. It was found to be spherical in shape with smooth surface.  
                 FORMULATION 1                                    FORMULATION 2 
“  
Fig 18: Scanning electron micrographs A) Formulation 1 B) Formulation 2 
 
Table 21: Vesicle diameter of Niosomes 
S.No Type of formulation Size (µm) 
1 F1 50 
2 F2 200 
  
Drug Entrapment Efficiency 
The quantity of the drug entrapped in the niosomes is very essential to know 
before studying the behaviours of the entrapped drug in physical or biological system.  
The process and formulation variables (cholesterol and surfactant) were altered and 
optimized to obtain the niosomes with maximum drug entrapment.  Two formulations 
FI and FII were subjected to percentage drug entrapment. 
The entrapment efficiency of drug in FII containing span 60 was found to be 
68% which showed maximum percent drug entrapment where as those containing 
span 40 was found to encapsulate 55%.  This showed that span 60 is the more suitable 
surfactant along with cholesterol for enhancing maximum entrapment for the drug 
Levetiracetam. 
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Further, the percent drug entrapment, is increased by decreasing the sonication 
time.  Therefore, the sonication time was optimized to 15 minutes and further 
reduction in the size by increasing sonication time was not attempted. 
Table 22: Percentage Drug Entrapment of the Formulated Niosomes 
 
 
 
 
 
 
In vitro Drug release 
The formulated niosomes were subjected to in vitro drug release using 0.1 M 
in a tubing.  The amount of Levetiracetam diffused was estimated 
spectrophotometrically at 220 nm.  FI showed 57.49% of drug release within 24 
hours.  FII showed 72.37% of drug release within 24 hours.  These results showed that 
Levetiracetam noisome has sustained release up to 24 hours. This is because the drug 
is released slowly for a prolonged period of time from Levetiracetam niosomes.  Also, 
therefore FII is selected for further studies like stability studies and pharmacological 
study. 
  
 
Formulation code 
 
% Drug entrapment 
 
FI(Span 40) 
 
 
55% 
 
FII(Span 60) 
 
 
68% 
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Table 23: In Vitro Drug Release of FI 
Time (hr) 
 
Percentage drug diffused 
30 14.85 ± 0.48 
1 17.23 ± 0.54 
2 20.29 ± 0.46 
3 22.46 ± 0.42 
4 23.57 ± 0.57 
5 30.40 ± 0.69 
6 34.42 ± 0.75 
7 37.02 ± 0.42 
8 41.75 ± 0.34 
9 45.14 ± 0.49 
10 47.36 ± 0.53 
11 50.31 ± 0.67 
12 55.89 ± 0.78  
13 57.70 ± 0.83 
14 59.97 ± 0.25 
15 62.24 ± 0.13 
16 66.13 ± 0.18 
17 70.25 ± 0.33 
18 71.68 ± 0.39 
19 73.21 ± 0.21 
20 77.94 ± 0.17 
21 81.28 ± 0.45 
22 86.17 ± 0.72 
23 88.77 ± 0.28 
24 90.52 ± 0.19 
                                 
                                       All the results were mean ± S.D (n꞊ 3). 
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Table 24: In Vitro Drug Release of F II 
Time (hr) 
 
Percentage drug diffused 
30 15.43 ± 0.35 
1 17.60 ± 0.26 
2 21.03 ± 0.57 
3 22.88 ± 0.51 
4 24.15 ± 0.46 
5 31.09 ± 0.11 
6 34.90 ± 0.39 
7 37.49 ± 0.41 
8 42.33 ± 0.49 
9 45.51 ± 0.13 
10 47.57 ± 0.48 
11 50.78 ± 0.37 
12 56.31 ± 0.08 
13 58.12 ± 0.21 
14 60.55 ± 0.12 
15 63.08 ± 0.28 
16 66.71 ± 0.69 
17 70.72 ± 0.47 
18 72.37 ± 0.13 
19 73.90 ± 0.55 
20 78.89 ± 0.17 
21 82.38 ± 0.66 
22 86.18 ± 0.53 
23 90.40 ± 0.10 
24 94.46 ± 0.37 
 
                                     All the results were mean ± S.D (n = 3). 
 
                                                                                                                               
Results and Discussion 
 
Dept of Pharmaceutics, KMCH College of Pharmacy       Page 54 
 
 
Release kinetics 
In-vitro release data obtained for the formulations was subjected to kinetic 
analysis. The cumulative percentage drug release data obtained were fitted to zero 
order, first order, Higuchi’s square root of time and equation to understand the 
mechanism of drug release from the Levetiracetam niosomal formulation. The 
diagrams were shown in Figure: 20-28. Higuchi model explains the diffusion 
controlled release mechanism. The slopes and the regression coefficient of 
determinations (R2) were listed in Table No: 25. The coefficient of determination 
indicated that the release data was best fitted with Higuchi’s kinetics.  
Kinetic modelling and release mechanisms 
 
Figure 19: Zero order plot of F1formulations 
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Figure 20: First order plot of F1 formulations 
 
 
Figure 21: Higuchi plot of F1 formulations 
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Figure 22: Zero order plot of F2 formulations            
 
 
Figure 23: First order plot of F2 formulations 
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Figure 24: Higuchi plot of F2formulations 
 
 
 
Kinetic Modeling Data 
Table No 25: Kinetic Modelling Data 
Formulation Zero order First order Higuchi model 
r2 r2 r2 
F2 0.996 0.931 0.935 
 
STBILITY STUDIES 
The result of accelerated stability studies, carried out according to ICH 
guidelines, The stability studies were performed for FII containing span 60.  The 
formulation was divided into three portions and stored at three different temperatures 
(i.e.) refrigeration temperature (40C 10C), room temperature and at 400C20C and 
RH 70% 5% for a period of three months.  Drug leakage from the niosomal 
formulation were analysed in terms of percent drug retained at the end of every 
month. 
Storage under refrigerated condition showed greater stability with 94.85% of 
drug content at the end of three months, whereas storage under room temperature and 
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at 400C  20C / R-H 70 %  5% showed drug content of 92.83% and 85.41% at the 
end of three months. 
Table 26: Stability Studies 
Temperature Amount of drug retained (%) after months  
 Initial I II III 
Refrigeration 
(40C10C 
 
100 97.42 96.22 94.85 
Room 
Temperature 
 
100 95.68 94.77 
 
 
92.83 
400C20C 
RH-70%  
5% 
100 89.79 87.73 85.41 
 
STERILITY TEST 
 Sterility test was done by I.P.1996. 
 After 7 days of observation, all the tubes containing sample was found to be 
sterile. 
ANTICONVULSANT ACTIVITY 
Table 27: Different stages of convulsion studies 
Groups Duration (sec) 
Flexion Extension Convulsion Stupor Death 
Control 1.52, 3.56, 
3.75, 2.84, 
3.16, 4.51 
21.46, 34.61, 
23.25, 18.56, 
15.92, 20.59 
8.91, 9.14, 
14.63, 11.50, 
9.12, 8.76 
156,121, 
186, 0, 
155, 0 
2/6 
Standard 4.19, 2.11, 
5.13, 2.62, 
3.14, 2.19 
2.81, 1.96, 
3.91,2.46, 
1.08, 0 
4.36, 4.59, 
8.83, 0, 0, 
3.61 
111, 123, 
125, 129, 
108, 105 
0/6 
Formulation 1.08, 1.28, 
5.13, 0.88, 
1.87, 1.71 
0.68, 1.63, 0, 
1.6, 0, 0 
4.6, 5.87, 0, 
1.38, 4.44, 
6.21 
77, 69, 91, 
86, 81, 94 
0/6 
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Table 28: Deviations obtained from convulsion studies 
Groups Duration (sec) 
Flexion Extension Convulsion Stupor Death 
Control 3.223333 ± 
0.4122513 
22.39833 ± 
2.650172 
10.34333 ± 
0.9525288 
103.000 ± 
33.63728 
2/6 
Standard 2.018333 ± 
0.3203167 
0.7066667 ± 
0.3590605** 
3.565 ± 
1.35183** 
108.500 ± 
6.716894 
0/6 
Formulation 2.701667 ± 
0.6589305 
1.981667 ± 
0.562645** 
3.750 ± 
1.023458** 
92.000 ± 
8.449852 
0/6 
Values are expressed as mean ± SEM (n=6); *p<0.05, **p<0.01 vs Control (Oneway 
ANOVA followed by Dunnett’s test) 
 
From the above tabular column it was concluded that formulation (F2) showed 
better anticonvulsant activity than the standard in lesser time. 
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SUMMARY 
The present study was aimed to prepare niosomes containing drug levetiracetam. It 
belongs to the class of drugs called anticonvulsant drug. They work by maximum stimulation 
with electrical current or different chemoconvulsants and showed only minimal activity in 
submaximal stimulation. Hence, the present work was made to formulate and evaluate the 
levetiracetam niosomes and compared its anti-convulsant activity with the pure drug. 
 FT-IR of pure drug and drug excipients mixture revealed no chemical interaction. Hence 
they were compatible. 
 UV Spectrophotometric method was developed for the determination of levetiracetam in 
7.4 pH phosphate buffer at 220nm. A regression coefficient value was found to be 0.99 
for levetiracetam. 
 Two formulations of levetiracetam niosomes were prepared by hand shaking method. 
 Formulation of  multilamellar  Niosomes vesicles were confirmed by examing the 
noisomal suspension under an TEM and observed the Internal Morphology  
 Various parameters like vesicle shape and entrapment efficiency were done for niosomes. 
Vesicle shape was analysed by SEM technique. The vesicles were found to be smooth 
and spherical in shape. Entrapment efficiency was noticed for F2 with 68%. 
 Niosomes were subjected to in-vitro diffusion studies. It reveals that F2 formulation has 
higher release with 94.46%. 
 The formulations were subjected to release kinetics and the best formulation was found to 
be F2 and its follows zero order kinetics. 
 Anticonvulsant activity of Niosomal formulations and the plain levetiracetam were 
conducted on 24 mice. It was found that niosomal formulation (F2) shows better activity 
than plain levetiracetam. 
 Stability studies were carried out at 4oC ± 1oC, 40oC ± 2oC RH-70% ± 5% and room 
temperature for 3 months. There were no significant changes in entrapment efficiency and 
in-vitro drug diffusion profile. 
 Sterility tests are performed for the optimized niosomal formulations, after 7 days 
observations all the tubes containing samples were found to be sterile. 
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CONCLUSION 
Levetiracetam niosomal formulation was prepared by hand shaking method and it 
was evaluated for its entrapment efficiency, in-vitro drug diffusion profile, sterility tests 
and stability studies. The optimized formulation F2 and levetiracetam plain were 
evaluated for it’s anti-convulsant activity using flexion, extension, convulsion, stupor, 
recovery and death. The effects produced by the formulation (F2) in the mice were 
comparable with that of the in-vitro drug diffusion profile. Hence, the present study 
concluded that the anti-convulsant activity of levetiracetam formulation (F2) shows 
better activity than the levetiracetam plain. 
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INTRODUCTION
TARGETED DRUG DELIVERY SYSTEM
DEFINITION:-
Drug Targeting can be defined as the ability to direct a
therapeutic agent specifically to desired site of action with
little (or) no interaction with non targeting tissue.
KMCH COLLEGE OF PHARMACY,  Dept. Of PHARMACEUTICS 3
NIOSOMES
 Niosomes are non-ionic surfactant vesicles obtained on
hydration of synthetic non-ionic surfactants,with (or) without
incorporation of cholestrol (or) other lipids.
 They are vesicular systems similar to liposomes that can be
used as carriers of hydrophilic and lipophilic drugs.
 It is less toxic and improves the therapeutic index of drug by
restricting its action to target cells.
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 Niosomes are novel drug delivery system,in which the
medication is encapsulated in vesicle.
 The niosomes are very small, and microscopic in size. Their
size lies in the nanometric scale.
 Niosomes are uni-lamellar (or) multi-lamellar vesicles. The
vescile is composed of a bilayer of non-ionic surface active
agents and hence the name niosomes.
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AIM AND OBJECTIVE
AIM:
• To formulate and evaluate Levetiracetam niosomes and
compare its anti-convulsant activity with the pure drug.
OBJECTIVE:
• To prepare and evaluate Levetiracetam niosomes .
• The need for present study is to encapsulate the drug in the 
niosomes vesicles for effective central nervous system drug 
delivery for the prolonged period of time.
• To compare the anti convulsant activity of Levetiracetam 
niosomes with a Levetiracetam pure drug.
• To formulate Levetiracetam in niosomal drug delivery there by 
dose can be minimised and also to achieve sustained release 
for a prolonged period of time.
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PLAN OF WORK
1. Pre-formulation studies
1. Solubility : To study the solubility behaviour of the drug with
different solvents.
2. FTIR: Identification of Levetiracetam pure drug by FTIR
technique.
3. DSC : To observe the compatibility of the product and
excipients used in the formulations.
2. Optimization of the formula
1. Optimization of excipients (surfactants)
2. Optimization of rotating speed
3. Optimization of temperature
3. To formulate the Levetiracetam niosomes with different surfactants
by liquid hydration technique using Rotory Flash Evaporator
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4.To characterize the formulated niosomes by following methods:
1. Surface Morphology.
2. Particle size distribution of the prepared niosomes.
3. Determination of entrapment efficiency.
5.To test the stability of the formulated niosomes.
6.To test the sterility of the formulated niosomes.
7.To examine the In vitro diffusion study of the niosomes
prepared with different surfactants and to compare their
drug release profile.
8.To Test the anti-convulsant activity of the formulated niosomes
with the formulation having best drug release.
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S. No Author’s 
Name
Journal Name Objective Conclusion
1
2
Raja K. et al
Rajesh Z. 
Mujoriya* 
kishordhamo
nder et al
International
journal Pharm
Tech.
Int J App 
Pharm
Formulated and 
evaluated the 
Maltodextrin based 
Proniosomal Drug 
Delivery System 
containing Anti-diabetic 
(Glipizide) drug.
Niosomes  drug
delivery system.
It was concluded that 
the formulation 
developed using the 
desirability approach 
produced high drug 
encapsulation efficiency 
and sustained anti-
diabetic activity in rats 
following oral 
administration.
It was concluded that 
Niosomes are thoughts 
to be better candidate’s 
drug delivery as 
compared to liposomes.
LITERATURE REVIEW
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Sl No Author’s 
Name
Journal Name Objective Conclusion
3
4
Anchal
Sankhyan
and Pravin
Pawar
Sakthivel et 
al
Journal of 
Applied 
Pharmaceutical 
Science.
Int J Pharm
Pharm Sci.
Recent Trends in 
Niosome as Vesicular 
Drug Delivery System.
Formulation and Invitro
Evalution of Niosomes 
contaninng
Oxacarbazepine.
It was concluded that 
Niosomes have evolved 
for treatment of many 
dreadful diseases 
efficiently with reduced 
side effects and better 
patient compliance.
Thus It was concluded 
that Thus the prepared 
noisome could be 
promising delivery 
system for 
Oxcarbazepine with 
sustained drug release 
profiles.
DRUG PROFILE
• Name                 : Levetiracetam
• Brand Name : Keppra
• Levetiracetam is an anticonvulsant medication used to treat 
epilepsy.
• Structure Levetiracetam :
• IUPAC Name        : (2R)-2-(2-oxopyrrolidin-1-yl)butanamide
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• Solubilty : Very soluble in water, Freely soluble in
Chloroform, Freely soluble in Methanol, Soluble in Ethanol,
Sparingly soluble in acetonitrile.
• Categoties : Anticonvulsants
Nootropic Agents
Pharmacokinetic profile of Levetiracetam
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Pharmacokinetic Characters Levetiracetam
bioavailability (%) ˷100%
protein binding (%) <10%
Volume of distribution(L/Kg) Not Available
% metabolized 24%
Elimination T1/2(hr) 6-8hrs
MATERIALS AND METHODOLOGY
S.NO. MATERIALS USED MANUFACTURER
1. Levetiracetam Lupin
2. Cholesterol Qualigens Fine Chemicals, Mumbai
3. Span 40 Kemphasol
4. Span 60 Kemphasol
5. Chloroform Ranbaxy
6. Diethylether Qualigens Fine Chemicals, Mumbai
7. Buffer (pH 7.4) Laboratory preparation
8. Mice Seiss Albino mice (25-30)
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List of Materials used
List of Equipments used
S.N
O.
EQUIPMENTS MANUFACTURER
1. Rotary Flash Evaporator Equitron Roteva,Medica 
Instrument Mfg-Co, Mumbai
2. Ultra Sonicator Vibronics
3. UV-Double Beam Spectrophotometer UV-Pharmaspec 1700, Shimadzu
4. Electronic Balance Sartorius
5. pH Meter Elico LI 120
6. Magnetic stirrer Remi- 1MLH
7. Environment stability testing chamber “HECO”. Environment chamber
8. FTIR Perkin Elmer
9. Centrifuge Remi
10. Scanning Electronic Microscope JEOL, JSM -6701 F, Japan
11. Particle size Analyzer Microtrac – Bluewave US
12. Anti convulsometer Kmch Laboratory
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• Compatibility studies:
The compatibility studies of drug with excipients were
done using FT-IR spectroscopy. The scanning range was
between 400- 4000cm-1
• Determination of λmax of Levetiracetam:
50 mg of accurately weighed drug was dissolved in the
phosphate buffer pH 7.4 which upon suitable dilution,
analyzed in UV spectrophotometer between 200 to 400 nm.
The point of absorption maximum obtained in the graph was
considered as the lmax of the pure drug.
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• Preparation of Niosomes
• Hand shaking method (Thin film hydration technique):
The mixture of vesicle forming ingredients like surfactant and
cholesterol are dissolved in a volatile organic solvent (diethyl
ether, chloroform or methanol) in a round bottom flask. The
organic solvent is removed at room temperature (20oc) using
rotator evaporator leaving a thin layer of solid mixture
deposited on the wall of the flask. The dried surfactant film
can be rehydrated with aqueous phase at 0-60oc with gentle
agitation. This process forms typical multilamellar Niosomes.
• Thermosensitive niosomes can be prepared by evaporating the
organic solvents at 60oc and leaving a thin film of lipid on the
wall of rotary flash evaporator. The aqueous phase containing
drug is then slowly added with intermittent shaking of flask at
room temperature followed by sonication.
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Formulation code FI FII
Amount of 
Levetiracetam
5mg 5mg
Cholesterol 5mg 5mg
Span40 5mg -
Span 60 - 5mg
Chloroform 5ml 5ml
Phosphate Buffer 5ml 5ml
Cholesterol surfactant 
ratio
1:1 1:1
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FORMULATION
EVALUATION OF LEVETIRACETAM NIOSOMES
• Entrapment efficiency
An1ml of the sample is taken and centrifuged at 13000 RPM at 40c
for 60 minutes using Eppendorf centrifuge. Supernatant was
separated without disturbing the sediment layer using micropipette.
Then the supernatant layer (free drug) was diluted using PBS pH 7.4
and analysed using UV spectrophotometer at 220 nm.
• Percent drug entrapment = amount of drug entrapped/initial
amount of drug*100
• Transmission Electron microscopic observation
The niosomal dispersion was spread on the glass slide
using a glass rod. Formation of multilamellar vesicles was
confirmed by examining the niosomal suspension under
an transmission electron microscope with the
magnification power of 71 lacks Sx.
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• Vesicle shape
The vesicle shape of best formulation F2 was determined by
using scanning electron microscopy.
• In-vitro diffusion studies
• The in-vitro diffusion of the drug through cellophane
membrane was performed.
• The cellophane membrane soaked in glycerin for 6-8 hours.
• Franz diffusion cell contains donor compartment and receiver
compartment
• Formulation was applied through donor compartment on the
dialysis membrane
• Reservoir compartment was filled with phosphate buffer.
• The study was carried at 37ºc at 100 rpm for 24hrs. samples
were withdrawn for every 1hr and absorbance measured at
220nm.
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• Release kinetics
The results of in vitro release profile obtained for all the
formulations were plotted in modes of data treatment as
follows.
Log cumulative percent drug remaining versus time (first
order kinetic model)
Cumulative percent drug release versus square root of time
(Higuchi’s model)
Cumulative percent drug release versus time (zero order
kinetic model)
Stability studies
• Stability testing of drug products begins as a part of drug
discovery and ends with the commercial product
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• To assess the drug and formulation stability, stability studies
were done. The stability studies were carried out for the most
satisfactory formulation.
• The most satisfactory formulation was sealed in a container
and kept at 4 ± 2°C and at Room temperaturefor 90 days.
At the end 90days, the sample was analyzed for the entrapment
efficiency percentage, and in vitro diffusion study.
ANTICONVULSANT ACTIVITY
Animals : Swiss Albino mice (25-30g)
Gender : Female
Number to be used : 24
Duration : 1 month
KMCH COLLEGE OF PHARMACY,  Dt. Of PHARMACEUTICS 21
GROUPING OF ANIMALS:
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Group TREATMENT : DOSE AND ROUTE OF 
ADMINISTRATION
NO OF ANIMALS (mice)
1. Control (only vehicle) 6
2. Only MES induced 6
3. MES with Standard
(Levetiracetam plain)
6
4. MES of Levetiracetam niosomes 6
RESULTS AND DISCUSSION
Determination of calibration curve:
Calibration curve of Levetiracetam at 220nm
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R² = 0.9928
y = 0.3815x
R² = 0.9928
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 1 2 3 4
Series1
Linear (Series1)
Linear (Series1)
Concentrat
ion (µg/ml)
Absorbance
0.5 0.225
1.5 0.427
2 0.602
2.5 0.935
3 1.106
Compatibility studies
KMCH COLLEGE OF PHARMACY,  Dt. Of PHARMACEUTICS
24
IR spectrum of levetiracetam
KMCH COLLEGE OF PHARMACY,  Dt. Of PHARMACEUTICS
25
4000 3500 3000 2500 2000 1500 1000 500
0
20
40
60
80
100
 
 
%
 T
ra
ns
m
itt
an
ce
 
Wavenumber cm
-1
CHOLESTEROL 
34
31
2935
2906
2866
2174 16
61
14
65
13
77
1448
1235
11
99
11
33
10
57
10
22
96
0
928
84
2
79
9
74
0
59
3
KMCH COLLEGE OF PHARMACY,  Dt. Of PHARMACEUTICS
26
IR SPECTRUM OF SPAN 40
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IR SPCTRA OF SPAN 60
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IR SPECTRA OF DRUG+CHOL+SPAN40
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IR SPECTRA OF DRUG+CHOL+SPAN60
DIFFERENTIAL SCANNING CALORIMETRY
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DSCof Levetiracetam pure drug
DSC of Cholesterol
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DSC of Span 40
DSC of Span 60
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DSC of Drug+ Cholesterol+Span40
DSCof Drug+ Cholesterol+Span60
S.NO SAMPLE MELTING POINT
1 Levetiracetam 192.53oC
2 Cholesterol 140.76oC
3 Span 40 53.14oC
4 Span 60 57.84oC
5 Drug+Cholesterol+Span 40 51.96oC
6 Drug+Cholesterol+Span 60 56.80oC
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DSC Observed  for the Drug and excipients
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OPTICAL MICROSCOPY (40X)  
FORMULATION 1 FORMULATION 2
• Transmission Electron microscopic observation:
Formation of multilamellar vesicles was confirmed by
examining the niosomal suspension under an transmission
electron microscope with the magnification power of 71 lacks
Sx and observe the internal morphology.
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Formulation 1 Formulation 2
SCANNING ELECTRON 
MICROSCOPY(538x,196x)
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FORMULATION 1 FORMULATION 2
SPAN 40: 50µm SPAN 60: 200µm
S.No
Formulation code % Drug entrapment
1
FI(Span 40) 55%
2
FII(Span 60) 68%
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Percentage Drug Entrapment of the Formulated Niosomes
Entrapment efficiency
IN VITRO RELEASE STUDIES
S.No % CR(F 1) % CR (F2)
0.3 14.85 15.43
1 17.23 17.60
2 20.29 21.03
3 22.46 22.88
4 23.57 24.15
5 30.40 31.09
6 34.42 34.90
7 37.02 37.49
8 41.75 42.33
9 45.14 45.51
24 90.52 94.46
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y = 3.2394x + 13.924
R² = 0.9949
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FORMULATION 1
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y = 0.1933x - 0.0552
R² = 0.9258
0
0.2
0.4
0.6
0.8
1
1.2
0 1 2 3 4 5 6
m
t/
m
i
SQUARE ROOT TIME
HIGUCHI ORDER KINETICS
F1 Linear (F1)
Higuchi order kinetics
y = 3.381x + 13.849
R² = 0.9965
0
20
40
60
80
100
0 5 10 15 20 25 30
%
C
R
Time
ZERO ORDER KINETICS f2 Linear (f2)
FORMULATION 2
Zero order kinetics
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y = -0.0501x + 2.0604
R² = 0.9314
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HIGUCHI ORDER KINETICS
F2
Linear (F2)
First order kinetics Higuchi order kinetics
S.No Kinetics model r2
1 Zero order 0.996
2 First order 0.931
3 Higuchi model 0.935
Kinetic modeling data
Stability studies:
Storage under refrigerated condition showed greater stability
with 94.85% of drug content at the end of three months,
whereas storage under room temperature and at 400C  20C /
R-H 70 %  5% showed drug content of 92.83% and 85.41%
at the end of three months.
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Temperature Amount of drug  retained (%) after month
Initial I II III
Refrigeration
(40C10C
100 97.42 96.22 94.85
Room Temperature 100 95.68 94.77 92.83
400C20C
RH-70%  5%
100 89.79 87.73 85.41
Sterility Test:
• Sterility test was done by I.P.1996.
• After 7 days of observation, all the tubes containing sample 
was found to be sterile.
ANTICONVULSANT ACTIVITY:
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Groups Duration (sec)
Flexion Extension Convulsion Stupor Death
Control 1.52, 3.56, 
3.75, 2.84, 
3.16, 4.51
21.46, 34.61, 
23.25, 18.56, 
15.92, 20.59
8.91, 9.14, 
14.63, 11.50, 
9.12, 8.76
156,121, 186, 
0, 155, 0
2/6
Standard 4.19, 2.11, 
5.13, 2.62, 
3.14, 2.19
2.81, 1.96, 
3.91,2.46, 
1.08, 0
4.36, 4.59, 
8.83, 0, 0, 
3.61
111, 123, 125, 
129, 108, 105
0/6
Formulation 1.08, 1.28, 
5.13, 0.88, 
1.87, 1.71
0.68, 1.63, 0, 
1.6, 0, 0
4.6, 5.87, 0, 
1.38, 4.44, 
6.21
77, 69, 91, 
86, 81, 94
0/6
Different stages of convulsion studies
Groups Duration (sec)
Flexion Extension Convulsion Stupor Death
Control 3.223333 ±
0.4122513
22.39833 ±
2.650172
10.34333 ±
0.9525288
103.000 ±
33.63728
2/6
Standard 2.018333 ±
0.3203167
0.7066667 ±
0.3590605**
3.565 ±
1.35183**
108.500 ±
6.716894
0/6
Formulation 2.701667 ±
0.6589305
1.981667 ±
0.562645**
3.750 ±
1.023458**
92.000 ±
8.449852
0/6
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Deviations obtained from convulsion studies
From the above tabular coloum it is concluded that
formulation(f2) shows better anticonvulsant activity than the
standard in lesser time.
SUMMARY
The present study was aimed to prepare niosomes containing
drug levetiracetam. It belongs to the class of drugs called
anticonvulsant drug. These drugs are used for the epilepsy.
They work by maximum stimulation with electrical current or
different chemoconvulsants and showed only minimal activity
in submaximal stimulation. Hence the present work was made
to formulate and evaluate the niosomes of levetiracetam by
intraperitoneal route of drug and the anticonvulsant activity is
to conduct on mice to find the best formulation.
• FT-IR of pure drug and drug excipients mixture revealed no
chemical interaction. Hence they were compatible.
• UV Spectrophotometric method was developed for the
determination of levetiracetam in 7.4 pH phosphate buffer at
220nm. A regression coefficient value was found to be 0.99 for
levetiracetam.
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• Two formulations of levetiracetam niosomes were prepared by
hand shaking method.
• Formulation of multilamellar niosomes vesicle were confirmed 
by examing the niosomal suspension under an TEM  and 
observed the internal morphology.
• Various parameters like vesicle shape and entrapment
efficiency were done for niosomes. Vesicle shape was analysed
by SEM technique. The vesicles were found to be smooth and
spherical in shape. Entrapment efficiency was noticed for F2
with 68%.
• Niosomes were subjected to in-vitro diffusion studies. It
reveals that F2 formulation has higher release with 94.46%.
• The formulations were subjected to release kinetics and the
best formulation was found to be F2 and its follows zero order
kinetics.
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• Anticonvulsant activity of Niosomal formulations and the
plain levetiracetam were conducted on 24 mice. It was
found that niosomal formulation (F2) shows better
activity than plain levetiracetam.
• Stability studies were carried out at 4oC ± 1oC, 40oC ±
2oC RH-70% ± 5% and room temperature for 3 months.
There were no significant changes in entrapment
efficiency and in-vitro drug diffusion profile.
• Sterility tests are performed for the niosomal
formulations, after 7 days observations all the tubes
containing samples was found to be sterile.
KMCH COLLEGE OF PHARMACY,  Dt. Of PHARMACEUTICS 47
CONCLUSION
• Levetiracetam niosomal formulation was prepared by
hand shaking method and it was evaluated for its
entrapment efficiency, in-vitro drug diffusion profile,
sterility tests and stability studies. The optimized
formulation F2 and levetiracetam plain were evaluated for
it’s anti-convulsant activity using flexion, extension,
convulsion, stupor, recovery and death. The effects
produced by the formulation (F2) in the mice were
comparable with that of the in-vitro drug diffusion profile.
Hence, the present study concluded that the anti-
convulsant activity of levetiracetam formulation (F2)
shows better activity than the plain levetiracetam.
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